Purpose: Clinicians use tamsulosin, an α1-adrenoceptor antagonist, to manage symptomatic benign prostatic hyperplasia (BPH). Because α1-adrenoceptors are also present in the brain, the potential exists for adverse effects on cognitive functions. We explored the association between tamsulosin use and dementia risk.
selectivity for the α1A subtype is unique to tamsulosin among all common α1-adrenoceptor antagonists indicated for BPH (ie, tamsulosin, doxazosin, terazosin, and alfuzosin). 12 While the important role of α1-adrenoceptors in cognitive neurophysiology has been previously acknowledged, recent evidence suggests that the α1A has different functions than the other subtypes. 7 Mice studies show that suppressed expression of the α1A-adrenoceptors is associated with poor cognitive performance. 13 By contrast, long-term stimulation of the α1A-adrenoceptors in mice improves synaptic plasticity, enhances learning and memory, and induces antidepressant-like behavior which can be reversed by the administration of an α1-adrenoceptor antagonist. 13, 14 A human study reported decreased expression of the α1A-adrenoceptors in the prefrontal cortex in dementia patients. 15 Given studies demonstrating that tamsulosin crosses the blood-brain-barrier, 16, 17 it is plausible that tamsulosin may exert adverse effects on cognitive functions by inhibiting the α1A-adrenoceptors in the central nervous system.
Little research has focused on the possible association of tamsulosin with cognitive impairment. Furthermore, as tamsulosin is often used in an older population of patients, and cognitive degeneration is a chronic process correlated with advanced ages, 18 the potential association between tamsulosin and cognitive impairment may be difficult to detect in day-to-day clinical practice. Therefore, we conducted a retrospective cohort study of incident dementia among Medicare beneficiaries diagnosed with BPH. We hypothesized that patients who used tamsulosin, as compared with patients who used no BPHmedication, and with patients who used alternative-BPH-medications (ie, doxazosin, terazosin, alfuzosin, dutasteride, or finasteride), would have an increased risk of dementia. baseline characteristics were examined during a 12-month look-back period before the index date. We excluded patients aged <66 years at the index date, had a dementia diagnosis before the index date or an insufficient look-back period of <12 months. Patients were also excluded if during the look-back period they had no BPH-related claims or interrupted Medicare Fee-for-Service enrollment.
We used 3 sets of comparison cohorts and applied the same eligibility criteria as for the tamsulosin cohort. Figure S1 , Supplementary Appendix). All patients were followed until one of the study end points: had incident dementia (event), were censored (death, start of a different BPH-medication, or loss of Medicare coverage), or reached the end of study (2012/12/31).
| Dementia case ascertainment
Dementia was defined based on the presence of ICD-9 codes for demen- and Alzheimer's disease (331.0). 19 Dementia was ascertained if, these ICD-9 codes were present in ≥1 inpatient, skilled nursing facility or home health agency claim(s), or ≥2 outpatient claims spaced ≥30 days apart. 20 This algorithm was used for both excluding dementia patients in the lookback period and identifying incident cases during the follow-up period.
To assess the impact of misclassification for dementia, we performed sensitivity analyses using more stringent criteria for case ascertainment during the follow-up period: patients had to have diagnosis code(s) present, and ≥1 prescription filled for dementia medications (ie, donepezil, rivastigmine, galantamine, and memantine).
| BPH medications
Medicare Part D files were used to identify patients who filled tamsulosin or the 5 alternative-BPH-medications. We used defined • The association between use of tamsulosin and the increased risk of dementia was observed among the US Medicare male beneficiaries who were diagnosed with BPH and older than 65 years.
• 25 We used diagnoses of delirium and mild cognitive impairment to control for patients' baseline cognitive status. We also considered the following health services utilization as proxies for general health status and access to healthcare: numbers of inpatient admissions, outpatient and emergency room visits, as well as use of a skilled nursing facility and/or home health agency (Table S3 , Supplementary Appendix).
| Propensity-score models
We constructed 6 different propensity-score models, each including the tamsulosin cohort and 1 of the 6 comparison cohorts. We estimated propensity-scores using multivariable logistic regression models with receipt of tamsulosin as the binary outcome variable. Based on estimated propensity scores, we separately matched patients in the tamsulosin cohort to patients in each of the 6 comparison cohorts at a 1:1 ratio using nearest-neighbor algorithm. 26, 27 Six matched cohortpairs were created: tamsulosin versus no-BPH-medication, doxazosin, terazosin, alfuzosin, dutasteride, and finasteride. To examine balance in each of the matched cohort-pairs, we used a standardized mean difference of less than 0.1 as an indication of negligible difference in covariates between 2 matched cohorts. 28 
| Statistical analysis
Separate Cox proportional hazard regression models were used in the 6 matched cohort-pairs to estimate hazard ratios (HR) and 95% confidence intervals (CI) for incident dementia during the follow-up period.
We adjusted for the same set of covariates which were used in the propensity-score models to reduce bias due to residual differences in the observed baseline covariates between the matched cohorts. 28 The primary analyses compared the risk of dementia in the tamsulosin cohort to the risk in each of the 6 comparison cohorts. To assess the robustness of the primary results, we conducted pre-specified sensitivity analyses when dementia cases were ascertained using the stringent criteria (combining the presence of ICD-9 codes and fills of dementia medications). We further performed a dose-response analysis including cumulative dose as a time-varying variable in the Cox regression model for all matched cohort-pairs except for the no-BPH-medication cohort. 29 Considering the distribution of cumulative dose at the end of follow-up (ie, events, censoring or end of study)
and practical implications, we used 4 cumulative dose categories in the analysis: 1 to 30 (reference level), 31 to 90 (low), 91 to 360 (medium), and 360+ DDDs (high). Cumulative dose in each matched cohort-pair is described in Table S4 , Supplementary Appendix. In addition, subgroup analyses were executed to test effect modification by age (65-74 years vs 75+ years) and race/ethnicity (white vs nonwhite). For both dose-response and subgroup analyses, we examined effect modification on a multiplicative scale using ratio of HRs, as well as on an additive scale using relative excess risk due to interaction (RERI). 30, 31 Details for the ratio of HRs and RERI can be found in Table   S5 , Supplementary Appendix. All statistical analyses were performed using SAS® Enterprise Guide v 7.1 (SAS Institute Inc., Cary, NC).
3 | RESULTS
| Baseline characteristics of the study cohorts
The final study sample included: tamsulosin cohort (n = 253 136); no- (Table 1) .
Propensity-score matching at a 1:1 ratio created 6 cohort-pairs:
tamsulosin versus no-BPH-medication (n = 161 729 in each cohort), doxazosin (n = 28 575), terazosin (n = 23 856), alfuzosin (n = 17 926), dutasteride (n = 34 009), and finasteride (n = 38 739). The distribution of propensity score among all cohort-pairs before matching is presented in Figure S3 , Supplementary Appendix. Baseline characteristics became very similar between the matched cohorts -the standardized mean differences for all covariates were less than 0.05, indicating a good balance achieved by matching (Table 2; and Table S3A -F in the Supplementary Appendix).
| Risk of dementia in Tamsulosin cohort vs comparison cohorts
Compared with the no-BPH-medication cohort, the tamsulosin cohort showed a significantly increased risk of dementia (incidence: 31.3 vs 25.9/1000 person-year; HR: 1.17; 95% CI: [1.14, 1.21]; Figure 1 ).
Use of tamsulosin was also associated with a significantly increased risk of dementia when compared with each of the 5 alternative-BPH-medication cohorts (HRs range from 1.11 to 1.26, all P ≤ 0.01; Figure 1 ). For a full list of baseline characteristics and standardized mean differences, please see Table S3 in the Supplemental Appendix. The number of patients in the tamsulosin cohort. The corresponding comparison cohort (ie, no-BPH-medication, doxazosin, terazosin, alfuzosin, dutasteride, or finasteride) has the same number of patients because matching was performed at a 1:1 ratio. 
| Sensitivity analysis

| Dose-response analysis
Results of dose-response analyses are summarized in Tables S6 and S7 in Supplementary Appendix).
To further understand the dose-effect, we examined within-drug Table 4, and Tables S6 and S7 in the Supplementary Appendix).
Most other matched cohort-pairs had similar results except for the within-drug HRs in finasteride and alfuzosin cohorts: the high dose level was associated with significantly increased dementia risk when compared with the reference dose level. However, when compared with the no BPH-medication cohort, neither medication showed an overall association with dementia (Table S9 , Supplementary Appendix).
| Subgroup analysis
Age or race groups did not significantly modify the association between tamsulosin use and dementia risk in almost all analyses. The no-BPH- 
| DISCUSSION
Our study explores the association between tamsulosin use and dementia risk among older men with BPH. Using a nationwide sample of the US Medicare beneficiaries, we found that men taking tamsulosin showed an increased risk of dementia when compared with the 6 comparison cohorts.
The dementia case ascertainment in our study was based on a validated algorithm using claims data. 20, 32 Taylor et al used the battery of ICD-9 codes from Medicare claims data and found a sensitivity of 87% for a sample of Alzheimer's disease patients. 19 Another study found that the battery of ICD-9 codes had a sensitivity of 77% and a specificity of 95%. 33 The crude incidence for dementia in our study (24.1 to 38.8 /1000 person-years) is comparable to estimates reported in a recent study on dementia in the US. 32 In addition, to minimize bias resulting from false positive cases, we included sensitivity analyses which identified dementia patients only when they filled dementia medications.
In these analyses, the association between use of tamsulosin and increased risk of dementia persisted in most cohort-pairs. The dementia incidence among men who used therapeutic treatment was 11.7-17.3/1000 person-years, very similar to the age-adjusted estimates Abbreviations: BPH, benign prostatic hyperplasia; CI, confidence interval; HR, hazard ratio. a Reference groups are doxazosin, terazosin, alfuzosin, dutasteride, finasteride, and no BPH-medication in respective pair-wise comparisons.
b Incidence (no. of cases /1000 person-years).
for moderate dementia in population studies. 34 These results suggest that our findings are robust for both mild and moderate cases of dementia.
It is possible that tamsulosin may just unmask symptoms in patients who have already developed early stage dementia rather than actually causing it. If this is the case, the following patterns should be observed: (1) tamsulosin is associated with only mild dementia but not moderate or severe cases; (2) the rate of dementia onset is higher at an early stage than a later stage following the initiation of tamsulosin regimen; and (3) higher cumulative dose not intensify the association between tamsulosin use and dementia risk.
However, our results showed otherwise. In addition to the strong results from our sensitivity analysis that focused primarily on moderate dementia, we presented cumulative incidence plots ( Figure S2 ) in the Supplementary Appendix. The cumulative incidence curves for tamsulosin and cohorts using alternative BPH-medications have similar shape and are almost linear, suggesting a stable rate of dementia onset over time. The difference in dementia risk between tamsulosin and other comparison cohorts is manifested only at later months during the follow-up. Last but not the least, the doseresponse analysis revealed that tamsulosin significantly increases dementia risk only when used at medium or high dose levels, but not at low dose levels. It is very difficult to establish a causal relationship in a non-randomized observational study, and we did not attempt this. Nonetheless, we believe that our results, especially those from the sensitivity and dose-response analyses, can provide important evidence for establishing robust links between tamsulosin use and dementia risk. 35 Previously published clinical trials did not report cognitive adverse effects of tamsulosin. This is not surprising because most of these studies had less than 100 subjects in the tamsulosin arm, less than 12 weeks of trial duration, or younger cohorts with mean ages ≤66 years. 5, 36, 37 Our study is the first to report a potential association between tamsulosin use and an increased risk of dementia among older patients with BPH. Tamsulosin does not show greater efficacy or tolerability than other common α1-adrenoceptor antagonists that are indicated for BPH. 1,2 Nonetheless, it is the most widely used BPH-medication. The popularity appears to be based primarily on the lack of need for dose titration because tamsulosin has a minimal impact on orthostatic blood pressure. 1, 5, 12 Convenient dosing, however, may not adequately balance the risk-benefit profile of tamsulosin regarding dementia and cognitive impairment. Considering the number of elderly 
| CONCLUSION
Older men diagnosed with BPH may face an increased risk of dementia when treated with tamsulosin. More research is needed to further investigate the neurophysiological mechanisms and clinical impact of tamsulosin on patients' cognitive well-being.
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